ARTICLE | Clinical News
CYC202: Began Phase I testing
February 26, 2001 8:00 AM UTC
Cyclacel Ltd., Dundee, U.K. Product: CYC202 Business: Cancer Therapeutic category: Apoptosis Target: Cyclin dependent kinase (CDK) 2 Description: Oral CDK2 inhibitor Indication: Treat cancer End po...